Trials / Completed
CompletedNCT03472014
Special Access Program IMVAMUNE®
A Special Access Program for the Prophylactic Vaccination With IMVAMUNE® for Personnel Working Directly With or in the Vicinity of Replicating Vaccinia Virus
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Bavarian Nordic · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Prophylactic smallpox vaccination for personnel actively working with or in the vicinity of replicating vaccinia virus
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IMVAMUNE® | IMVAMUNE® liquid -frozen, containing 1 x 10E8 TCID50 MVA-BN® per 0.5 mL dose |
Timeline
- Start date
- 2010-04-22
- Primary completion
- 2014-11-14
- Completion
- 2014-11-14
- First posted
- 2018-03-21
- Last updated
- 2020-08-19
- Results posted
- 2020-08-19
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03472014. Inclusion in this directory is not an endorsement.